HanAll BioPharma Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (1973)
Status: Acquired by Daewoong Pharmaceutical Co. LTD. (2015)

Organization Overview

First Clinical Trial
2010
NCT01232036
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

HanAll BioPharma Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Dry Eye Syndromes (Phase 3)

Eczema (Phase 2)

Essential Hypertension (Phase 3)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hyperlipidemias (Phase 3)

Hyperlipoproteinemias (Phase 3)

Hypertension (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Prostatic Neoplasms (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 14